Image

Europe Fibrotic Diseases Treatment Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Europe Fibrotic Diseases Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Mar 2023
  • Europe
  • 350 Pages
  • No of Tables: 136
  • No of Figures: 36

Europe Fibrotic Diseases Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD MILLION
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Europe Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2030.

Europe Fibrotic Diseases Treatment Market

Europe Fibrotic Diseases Treatment Market Analysis and Insights

Europe fibrotic diseases treatment market is driven by the factors such as the rising prevalence of fibrotic diseases, an increase in the number of people smoking cigarettes, and technological advancement in the treatment of fibrosis diseases, leading to market growth. Currently, healthcare expenditure has increased across developed and emerging countries which is expected to create a competitive advantage for manufacturers to develop new and innovative products.

Europe Fibrotic Diseases Treatment MarketEurope Fibrotic Diseases Treatment Market

Europe fibrotic diseases treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers which propelled the demand of the market in the forecast period.

Europe fibrotic diseases treatment market is supportive and aims to reduce the progression of the diseases. Data Bridge Market Research analyses that the Europe fibrotic diseases treatment market will grow at a CAGR of 6.0% during the forecast period of 2022 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2021

Historic Years

2020 (Customizable to 2015- 2020)

Quantitative Units

Revenue in USD Thousand, Pricing in USD, Volume in Units

Segments Covered

By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

Countries Covered

Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe

Market Players Covered

Boehringer Ingelheim International GmbH, AbbVie Inc., Redx Pharma Plc, Bristol-Myers Squibb Company, Gilead Sciences, Inc.,  KITHER BIOTECH S.R.L., Verona Pharma plc,  Intercept Pharmaceuticals, Inc., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH among others.

Market Definition

The term fibrosis describes the development of fibrous connective tissue as a reparative response to injury or damage. Fibrosis may refer to the connective tissue deposition that occurs as part of normal healing or to the excess tissue deposition that occurs as a pathological process. Diseases characterized by uncontrolled, progressive fibrosis include Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), and Systemic Sclerosis (SSc).

Fibrosis is a group of serious organ/tissue diseases that affect the tissue system. Fibrosis scars and thickens the tissue. It impacts the connecting tissue, for instance, in the lung and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time. Hard, stiff lung tissues don't expand as well as they should, making it harder to breathe. Pulmonary fibrosis may cause shortness of breath when you do routine tasks that never seemed tiring before.

Europe Fibrotic Diseases Treatment Market Dynamics

Drivers

  • Rising prevalence of fibrotic diseases

Due to various risk factors such as aging, obesity, high blood pressure (hypertension), or family history of fibrotic disease, patients with fibrotic diseases are rising globally and becoming a significant socio-economic issue. Thus, the rising number of patients with fibrotic diseases increases the demand for treatment, which act as a driver in the fibrotic diseases treatment market.

  • Increase in the number of people smoking cigarettes

Cigarette smoking is one of the most recognized risk factors for the development of Idiopathic Pulmonary Fibrosis (IPF). Furthermore, recent work suggests that smoking may have a detrimental effect on the survival of patients with IPF. The mechanism by which smoking may contribute to the pathogenesis of IPF is largely unknown. However, accumulating evidence suggests that increased oxidative stress might promote disease progression in IPF patients who are current and former smokers.

Thus cigarette smoke contains particulate matter as well as numerous chemicals, including highly toxic RONS, which increases the swelling inside the body and hence lead to various diseases, including pulmonary fibrosis, cancer among others, which is expected to drive the growth of fibrotic diseases treatment market.

  • Technological advancement in the treatment of fibrosis diseases

IPF is characterized by the progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2–4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant, or trial recruitment. Significant recent advances in the field have led to two novel anti-fibrotic agents, pirfenidone and nintedanib, which have been shown to significantly slow disease progression in IPF.

Thus increasing technological advancements for the detection and treatment of fibrotic diseases is expected to drive the growth of the fibrotic diseases treatment market.

Opportunities

  • Rising research and development activities

The research and development activities have significantly opened various ways for the treatment of several diseases. The emerging technological advancements, along with the appropriate research, lead to the formation of several drugs for the treatment of diseases. Most people associate a company's research and development function with the invention of new products. While inventions are important, the development of existing products is of equal significance as consumer preferences are continually changing.

Thus, rising research and development activities for fibrotic disease medications and treatment are expected to act as opportunities for the growth of the fibrotic diseases treatment market.

  • Development of new and more effective therapies for fibrotic diseases

There are very few treatment options available for fibrotic diseases. These include medication which includes pirfenidone and nintedanib, oxygen therapy, organ transplantation, and pulmonary rehabilitation.

Hence the rising development of new and more effective therapies for fibrotic diseases will provide new opportunities in the fibrotic diseases treatment market.

Restraints/Challenges

  • High cost of medication and treatments

Fibrotic disease treatments have become increasingly expensive due to the growing number of patients suffering from fibrosis and the risen prices of medical devices and medications. The modern technological devices used in fibrosis treatment are also playing a significant role in the high prices of treatments, and high accuracy, providing a definitive diagnosis for Idiopathic Pulmonary Fibrosis (IPF). Therefore, the high cost of medications and treatment procedures for fibrotic disease is hampering the market's growth.

Hence, the high cost associated with the medication and treatment of fibrotic disease is expected to restrict the growth of the fibrotic diseases treatment market.

  • Lack of effective biomarkers and diagnostic tools for early detection and monitoring of fibrotic diseases

Biomarkers can be measurements of physiological and pathological processes or drug effects. For instance, they can distinguish the disease from health or other similar diseases (a diagnostic); they can predict mortality, exacerbation, and disease progression (a prognostic); and as well as predict a response to therapy (a theranostic).

Therefore, the limited availability of chest imaging in developing countries is considered a chief obstacle to diagnosis since high-resolution computed tomography of the chest is the key diagnostic test for Idiopathic Pulmonary Fibrosis (IPF). Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries, which is expected to restrain the growth of the fibrotic diseases treatment market.

  • The complex and multifactorial nature of fibrotic diseases.

Although complex fibrotic disorders often cluster in families, they do not have a clear-cut pattern of inheritance. It may be difficult to identify the role of genetics in these disorders, particularly because families often also share environments and may have similar lifestyles. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified.

Hence the complex and multifactorial nature of fibrotic disease is expected to challenge the fibrotic diseases treatment market.

Recent Development

  • In May 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and ArisGlobal, the Europe market leader in drug safety solutions worldwide, announced the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal's technology platform, LifeSphere, under the name of LifeSphere Clarity and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety. This has helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the Europe presence in the market
  • In March 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb acquired Turning Point Therapeutics for USD 76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and was anticipated to close during the third quarter of 2022. This acquisition has helped the company to increase its Europe presence in the market.

Europe Fibrotic Diseases Treatment Market Segmentation

The Europe fibrotic diseases treatment market is categorized into four notable segments based on treatment, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Treatment

  • Medication
  • Organ Transplantation
  • Oxygen Therapy
  • Others

On the basis of treatment, the fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others.

Application

  • Idiopathic pulmonary fibrosis
  • Hepatic cirrhosis
  • Renal fibrosis
  • Cutaneous fibrosis
  • Others

On the basis of application, the fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.

End User

  • Government organization
  • Hospitals
  • Academic and research institutes
  • Others

On the basis of end user, the fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others.

Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Others

On the basis of distribution channel, the fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others.

Fibrotic Diseases Treatment Market

Europe Fibrotic Diseases Treatment Market Regional Analysis/Insights

The Europe fibrotic diseases treatment market is analyzed, and market size insights and trends are provided by treatment, application, end user, and distribution channel, as referenced above.

The countries covered in the Europe fibrotic diseases treatment report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, and the rest of Europe.

Germany is expected to dominate Europe fibrotic diseases treatment market due to increasing technological advancement in developing areas.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and the challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Fibrotic Diseases Treatment Market Share Analysis

Europe fibrotic diseases treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on Europe fibrotic diseases treatment market.

Some players in the market are Boehringer Ingelheim International GmbH, AbbVie Inc., Redx Pharma Plc, Bristol-Myers Squibb Company, Gilead Sciences, Inc.,  KITHER BIOTECH S.R.L., Verona Pharma plc,  Intercept Pharmaceuticals, Inc., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH among others.


SKU-

TABLE 1 EUROPE FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 EUROPE RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 24 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 25 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 26 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 27 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 28 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 29 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 30 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 31 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 32 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 33 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 34 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 35 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 36 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 37 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 38 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 39 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 40 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 41 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 42 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 43 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 44 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 45 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 46 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 47 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 48 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 49 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 50 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 51 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 52 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 53 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 54 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 55 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 56 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 57 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 58 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 59 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 60 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 61 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 62 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 63 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 64 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 65 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 66 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 67 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 68 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 69 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 70 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 71 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 72 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 73 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 74 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 75 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 76 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 77 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 78 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 79 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 80 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 81 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 82 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 83 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 84 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 85 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 86 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 87 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 88 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 89 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 90 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 91 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 92 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 93 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 94 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 95 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 96 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 97 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 98 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 99 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 100 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 101 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 102 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 103 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 104 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 105 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 106 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 107 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 108 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 109 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 110 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 111 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 112 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 113 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 114 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 115 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 116 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 117 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 118 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 119 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 120 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 121 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 122 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 123 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 124 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 125 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 126 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 127 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 128 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 129 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 130 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 131 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)

TABLE 132 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 133 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 134 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 135 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 136 REST OF EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Europe Fibrotic Diseases Treatment Market is projected to grow at a CAGR of 6.0% during the forecast period by 2030.
The Europe Fibrotic Diseases Treatment Market is segmented on the basis of treatment, application, end user, and distribution channel.
The major players in the Europe Fibrotic Diseases Treatment Market are Boehringer Ingelheim International GmbH, AbbVie Inc., Redx Pharma Plc, Bristol-Myers Squibb Company, Gilead Sciences, Inc., KITHER BIOTECH S.R.L., Verona Pharma plc, etc.
The countries covered in the Europe Fibrotic Diseases Treatment Market are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials